A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

Travere Therapeutics TVTX announced that the FDA granted full approval to its oral non-immunosuppressive drug Filspari ...

The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare ...

progressive kidney disease and a leading cause of kidney failure due to glomerular disease. The FDA early last year had granted conditional approval of the drug, subject to confirmatory study results.

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

On Friday, the U.S. Food and Drug Administration approved ... progression of eczema. The FDA's approval is a "big win for ...

Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III ...

Independent advisers to the U.S. Food and Drug Administration voted on Friday against confirmatory trial data for Intercept Pharmaceuticals' liver disease drug, putting into question the treatment's ...

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in ...

Returning to Boston this December, the 4th annual Rare & Genetic Kidney Disease Drug Development Summit will unite 30+ experts speakers including Novartis, FDA, XORTX Therapeutics, Walden Biosciences, ...

Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the ...

Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...